VRSEF Verisante Technology Inc (CE)

Edison Research Initiates Coverage on Verisante Technology, Inc.

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 3, 2014) - Verisante Technology, Inc. (TSX-VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that Edison Research, an investment research firm, has initiated coverage on the Company.

The report on Verisante is now available for download from Edison's website at: http://www.edisoninvestmentresearch.com/research/company/verisante-technology

About Edison Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington.

Companies of all sizes benefit from our research service where we provide the highest standards of research and unrivalled distribution of our reports on a truly global and unrestricted basis. Our corporate services also include an Investor Access Service where we actively market companies to professional investors, with a particular focus on private client wealth managers, and a Commercial Due Diligence Service where we assist companies, private equity houses and corporate finance teams in identifying and assessing potential corporate transactions.

Edison also provides a highly valued service to institutional investors, and our client list includes a large number of Europe's leading investment institutions. These investors are serviced by a dedicated team who provide them with access to our analysts, bespoke research and alpha-generating investment ideas.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan, Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

Verisante Technology, Inc.Thomas BraunPresident & CEOTelephone: (604) 605-0507Email: info@verisante.comWebsite: www.verisante.comYoutube: www.youtube.com/verisanteTwitter: www.twitter.com/verisanteFacebook: www.facebook.com/verisante